Agios Pharm share price logo

Agios Pharm Share Price

NASDAQ: AGIO

Small Cap

$25.74

-0.98

(-3.67%)

as on

Agios Pharm Stock Performance

as on April 24, 2026 at 2:37 pm IST

  • Day's Low

    Day's High

    $25.62
    $26.94
    downward going graph

    0.47%

    Downside

    4.66%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $22.24
    $46.00
    downward going graph

    13.60%

    Downside

    78.71%

    Upside

    downward going graph

Agios Pharm share price movements today

Previous Close
$26.72
Open
$26.87
Volume
966.4K
Day's Low - High
$25.62 - $26.94
52 Week Low - High
$22.24 - $46.00

Agios Pharm Historical Returns

1 Month Return
-4.94 %
3 Month Return
-6.38 %
1 Year Return
-5.82 %
3 Year Return
+ 17.81 %
5 Year Return
-51.18 %

Agios Pharm Stock Fundamentals & Key Indicators

Check Agios Pharm market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.6B

EPS (TTM)

-6.51

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-467.0M

Revenue (TTM)

54.0M

Profit Margin

0.00%

Return On Equity TTM

-30.20%

Agios Pharm vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Agios Pharm with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$1.6B-51.18%NA0.00%
BUY$41.2B127.17%131.818.45%
BUY$111.1B100.86%28.532.94%
NA$34.7BNA126.485.37%
BUY$79.0B52.79%18.0231.41%

Stock Returns calculator for Agios Pharm Stock including INR - Dollar returns

The Agios Pharm stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Agios Pharm investment value today

Current value as on today

₹1,00,015

Returns

₹15

(+0.02%)

Returns from Agios Pharm Stock

-₹9,270 (-9.27%)

Dollar Impact

₹9,286 (+9.29%)

Analyst Recommendation on Agios Pharm Stock

Based on 15 analysts

BUY

73.33%

Buy

26.67%

Hold

0.00%

Sell

Based on 15 analysts, 73.33% of analysts recommend a 'BUY' rating for Agios Pharm. Average target price of $41.5

Agios Pharm Share Price Target

Get share price movements and forecasts by analysts on Agios Pharm.

What analysts predicted

37.98%UPSIDE

Target Price

$41.5

Current Price

$25.74

Analyzed by

15 Analysts

Target

$41.50

Agios Pharm target price $41.5, a slight upside of 37.98% compared to current price of $25.74. According to 15 analysts rating.

Agios Pharm Stock’s Investor Sentiment and Interest

Investment in Agios Pharm Shares on INDmoney has grown by 1116.66% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:1116.66% versus previous 30 day period

Search interest for Agios Pharm Stock has increased by 154% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:154% versus previous 30 day period

Agios Pharm Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
7
7
8
8
8
10
8
12
12
19
Gross Profit
6
5
6
5
8
9
7
9
11
19
Operating Income
-100
-106
-92
-105
-102
-125
-106
-127
-116
-121
EBITDA
-99
-104
-90
-104
-101
-123
-105
-110
-102
-120
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
1
1
1
1
Income Before Tax
-91
-95
-81
-96
1,001
-105
-89
-112
-103
-109
Income Tax Expense
-9
1
1
-
53
-8
-
-
-
-1
Net Income
-91
-95
-81
-96
947
-96
-89
-112
-103
-108
Net Profit Margin
-1234.27%
-1350.70%
-995.84%
-1115.71%
10574.69%
-899.56%
-1023.25%
-899.40%
-803.05%
-541.09%

Agios Pharm Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
69
43
94
117
203
0
14
26
36
54
Gross Profit
69
43
92
116
-18
-18
12
17
32
47
Operating Income
-200
-320
-362
-426
-335
-378
-389
-391
-425
-472
EBITDA
-195
-314
-355
-394
-310
-337
-380
-384
-420
-466
Interest Expense
2
6
16
14
17
0
12
-
-
-
Depreciation
-
6
7
8
9
9
8
6
5
5
Income Before Tax
-198
-314
-346
-411
-329
-356
-231
-352
717
-413
Income Tax Expense
-5
-6
32
-14
7
-1,977
-157
6
44
-1
Net Income
-198
-314
-346
-411
-327
1,604
-231
-352
673
-412
Net Profit Margin
-283.97%
-731.60%
-366.61%
-348.97%
-161.11%
3875280.74%
-1627.82%
-1312.63%
1845.92%
-764.01%

Agios Pharm Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-95
-81
-96
947
-96
-89
-112
-103
-108
Operating Cash Flow
-72
-99
-72
-84
-133
-111
-77
-88
-96
Investing Cash Flow
95
124
37
250
-49
112
78
95
90
Financing Cash Flow
0
5
1
2
4
1
0
4
2
Change in Cash
23
30
-34
169
-177
2
1
11
-3

Agios Pharm Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-314
-346
-411
-329
-356
-231
-352
673
-412
Operating Cash Flow
-285
-304
-370
-290
-407
-309
-296
-389
-372
Investing Cash Flow
-57
-273
91
75
1,248
243
239
363
377
Financing Cash Flow
285
546
289
261
-765
2
5
14
8
Change in Cash
-58
-32
10
46
75
-63
-51
-11
12

Global Institutional Holdings in Agios Pharm

Funds
Holdings
Farallon Capital Management, L.L.C.
8.81%
Deutsche Bank AG
1.58%
BlackRock Inc
7.76%
Citadel Advisors Llc
1.86%
Macquarie Group Ltd
3.34%

Agios Pharm News & Key Events

  • img

    Today's Timeline - 24 December

    Wed, 10:37 AM

    -

    Agios Pharmaceuticals announces FDA approval for AQVESME (mitapivat) for anemia in thalassemia, shares fell 1.4% to $24.59.

    Wed, 06:01 PM

    -

    Agios shares rise 9.80% to $27.00 premarket after FDA approval of AQVESME for thalassemia-related anemia.

    Wed, 06:48 PM

    -

    FDA expands approval for mitapivat, expected to generate $320 million additional peak revenue opportunity.

  • img

    Today's Timeline - 24 December

    Wed, 10:33 PM

    -

    Management outlines marketing plans for AQVESME, targeting 4,000 patients with a price of $425,000 annually.

Insights on Agios Pharm

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 8.72M → 19.96M (in $), with an average increase of 22.9% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 51.7% return, outperforming this stock by 33.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 28.0% return, outperforming this stock by 36.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -103.43M → -108.03M (in $), with an average decrease of 4.5% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, AGIO stock has moved down by -24.0%

About Agios Pharm

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
OrganisationAgios Pharm
Headquarters88 Sidney Street, Cambridge, MA, United States, 02139
IndustryBiotechnology
CEOMr. Brian M. Goff M.B.A.
E-voting on sharesClick here to vote

Key Management of Agios Pharm

Name

Title

Ms. Cecilia Jones

Chief Financial Officer

Mr. James William Burns

Corporate Secretary & Chief Legal Officer

Dr. Sarah Gheuens M.D., Ph.D.

Chief Medical Officer and Head of Research & Development

Ms. Tsveta Milanova

Chief Commercial Officer

Dr. Shin-San Su Ph.D.

Co-Founder

Mr. Brian M. Goff M.B.A.

CEO & Director

Dr. Lewis clayton Cantley Ph.D.

Co-Founder

Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.

Co-Founder

Dr. Craig B. Thompson M.D.

Co-Founder

Mr. T. J. Washburn

VP, Controller & Principal Accounting Officer

FAQs

What is Agios Pharm share price today?

Agios Pharm share price today is $25.74 as on at the close of the market. Agios Pharm share today touched a day high of $26.94 and a low of $25.62.

What is the 52 week high and 52 week low for Agios Pharm share?

Agios Pharm share touched a 52 week high of $46 on and a 52 week low of $22.24 on . Agios Pharm stock price today i.e. is closed at $25.74,which is 44.04% down from its 52 week high and 15.74% up from its 52 week low.

What is Agios Pharm's market capitalisation today?

Agios Pharm market capitalisation is $0.00T as on .

How to invest in Agios Pharm Stock (AGIO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Agios Pharm on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Agios Pharm Shares that will get you 0.0583 shares as per Agios Pharm share price of $25.74 per share as on April 24, 2026 at 9:07 am IST.

What is the minimum amount required to buy Agios Pharm Stock (AGIO) from India?

Indian investors can start investing in Agios Pharm (AGIO) shares with as little as ₹94.085 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹940.85 in Agios Pharm stock (as per the Rupee-Dollar exchange rate as on ). Based on Agios Pharm share’s latest price of $25.74 as on April 24, 2026 at 9:07 am IST, you will get 0.3885 shares of Agios Pharm. Learn more about fractional shares .

What are the returns that Agios Pharm has given to Indian investors in the last 5 years?

Agios Pharm stock has given -51.18% share price returns and 24.28% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?